Stephens Investment Management Group LLC Has $15.53 Million Holdings in BioLife Solutions, Inc. $BLFS

Stephens Investment Management Group LLC lifted its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 14.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 608,814 shares of the medical equipment provider’s stock after purchasing an additional 77,095 shares during the quarter. Stephens Investment Management Group LLC’s holdings in BioLife Solutions were worth $15,531,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its stake in BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 441 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of BioLife Solutions by 2.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock worth $454,000 after buying an additional 500 shares during the last quarter. Isthmus Partners LLC grew its holdings in shares of BioLife Solutions by 0.4% in the 2nd quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after acquiring an additional 509 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of BioLife Solutions by 2.7% in the second quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock valued at $447,000 after acquiring an additional 555 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of BioLife Solutions by 2.6% in the second quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock valued at $588,000 after acquiring an additional 702 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BLFS shares. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a research report on Monday, December 29th. Wall Street Zen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. UBS Group restated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Finally, Northland Securities set a $34.00 target price on shares of BioLife Solutions in a report on Monday, January 5th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $32.00.

Insider Buying and Selling

In related news, Director Amy Duross sold 4,523 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $24.51, for a total value of $110,858.73. Following the transaction, the director owned 25,687 shares in the company, valued at approximately $629,588.37. This trade represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joydeep Goswami sold 1,666 shares of the company’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $28.99, for a total transaction of $48,297.34. Following the sale, the director directly owned 44,986 shares of the company’s stock, valued at $1,304,144.14. This represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 187,741 shares of company stock worth $4,896,818 in the last quarter. Insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Down 0.2%

Shares of BioLife Solutions stock opened at $24.42 on Friday. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -348.81 and a beta of 1.93. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62. The company has a 50-day simple moving average of $25.13 and a two-hundred day simple moving average of $24.95.

BioLife Solutions Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.